Document 0035
 DOCN  M9470035
 TI    Potent inhibition of human immunodeficiency virus type 1 replication by
       an intracellular anti-Rev single-chain antibody.
 DT    9409
 AU    Duan L; Bagasra O; Laughlin MA; Oakes JW; Pomerantz RJ; Dorrance H.
       Hamilton Laboratories, Department of Medicine,; Jefferson Medical
       College, Thomas Jefferson University,; Philadelphia, PA 19107.
 SO    Proc Natl Acad Sci U S A. 1994 May 24;91(11):5075-9. Unique Identifier :
       AIDSLINE MED/94255473
 AB    Human immunodeficiency virus type 1 (HIV-1) has a complex life cycle,
       which has made it a difficult target for conventional therapeutic
       modalities. A single-chain antibody moiety, directed against the HIV-1
       regulatory protein Rev, which rescues unspliced viral RNA from the
       nucleus of infected cells, has now been developed. This anti-Rev
       single-chain construct (SFv) consists of both light and heavy chain
       variable regions of anti-Rev monoclonal antibody, which, when expressed
       intracellularly within human cells, potently inhibits HIV-1 replication.
       This intracellular SFv molecule is demonstrated to specifically
       antagonize Rev function. Thus, intracellular SFv expression, against a
       retroviral regulatory protein, may be useful as a gene therapeutic
       approach to combat HIV-1 infections.
 DE    Amino Acid Sequence  Animal  Blotting, Northern  Fluorescent Antibody
       Technique  Gene Products, rev/*IMMUNOLOGY  Hela Cells  Human  HIV
       Antibodies/GENETICS/*IMMUNOLOGY  HIV-1/*IMMUNOLOGY  Mice  Molecular
       Sequence Data  Support, Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.
       Transfection  Virus Inhibitors  Virus Replication  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).